Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 May-Jun;46(3):334-6.
doi: 10.4103/0253-7613.132189.

Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma

Amrita Sil  1 , Nilay Kanti Das  2
Affiliations
Case Reports

Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma

Amrita Sil et al. Indian J Pharmacol. 2014 May-Jun.

Abstract

Sorafenib, a multikinase inhibitor, is approved for treatment of renal cell cancer and hepatocellular cancer. Hand-foot syndrome (HFD) is a condition where erythema, scaling, and bullous lesion affect the hand and feet. In this case, a post-nephrectomy renal carcinoma patient prescribed sorafenib developed HFD 1 week after the drug usage. All laboratory parameters were within normal limits. The dose of sorafenib was reduced and topical corticosteroids, antihistamines, and emollients were prescribed. The reaction reduced after 2 weeks of therapy, only to reappear again when the second cycle of sorafenib-targeted therapy was started. The case was diagnosed as sorafenib-induced HFD.

Keywords: Hand-foot syndrome; renal cell carcinoma; sorafenib.

PubMed Disclaimer

Conflict of interest statement

Conflict Interest: No

Figures

Figure 1
Figure 1
Tense vesicles and bullae over palmer surface of tip of fingers and interphalangeal joints
Figure 2
Figure 2
Focal hyperkeratosis over the pressure points of sole
Figure 3
Figure 3
Healed bullae on completion of sorafenib-targeted therapy and treatment with topical clobetasol
See this image and copyright information in PMC

References

    1. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol. 2009;60:299–305. - PubMed
    1. Demirçay Z, Gürbüz O, Alpdoğan T, Yücelten D, Alpdoğan O, Kurtkaya O, et al. Chemotherapy-induced acral erythema in leukemic patients: A report of 15 cases. Int J Dermatol. 1997;36:593–8. - PubMed
    1. McLellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther. 2011;24:396–400. - PubMed
    1. Uppsala: The Uppsala Monitoring Centre; 2005. [Last accessed on 2013 Jul 16]. The use of the WHO-UMC system for standardized case causality assessment [monograph on the Internet] Available from: http://www.who-umc.org/graphics/4409.pdf .
    1. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45. - PubMed

Publication types

MeSH terms